• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.

作者信息

Bilgin Burak, Şendur Mehmet An, Hızal Mutlu, Akıncı Muhammed Bülent, Şener Dede Didem, Yalçın Bulent

机构信息

Yıldırım Beyazıt University, Faculty of Medicine, Department of Medical Oncology, 06800, Bilkent, Ankara, Turkey.

出版信息

Future Oncol. 2017 Sep;13(22):1911-1913. doi: 10.2217/fon-2017-0270. Epub 2017 Aug 22.

DOI:10.2217/fon-2017-0270
PMID:28829190
Abstract
摘要

相似文献

1
Docetaxel or abiraterone in addition to androgen deprivation therapy in metastatic castration-sensitive prostate cancer.多西他赛或阿比特龙联合雄激素剥夺疗法用于转移性去势敏感性前列腺癌治疗
Future Oncol. 2017 Sep;13(22):1911-1913. doi: 10.2217/fon-2017-0270. Epub 2017 Aug 22.
2
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches.靶向转移性激素敏感型前列腺癌：化疗联合激素治疗及新的联合治疗策略
J Urol. 2019 May;201(5):876-885. doi: 10.1097/JU.0000000000000117.
3
Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.在 GETUG-AFU 15 期 3 期试验中，对于转移性去势敏感前列腺癌，在雄激素剥夺治疗联合或不联合多西他赛治疗的男性患者中，进展后接受的治疗的抗癌活性和耐受性。
Eur Urol. 2018 May;73(5):696-703. doi: 10.1016/j.eururo.2017.09.022. Epub 2017 Oct 23.
4
Abiraterone acetate/androgen deprivation therapy combination versus docetaxel/androgen deprivation therapy combination in advanced hormone-sensitive prostate cancer: a network meta-analysis on safety and efficacy.醋酸阿比特龙/雄激素剥夺疗法联合方案与多西他赛/雄激素剥夺疗法联合方案治疗晚期激素敏感性前列腺癌的疗效与安全性的网状Meta分析
Curr Med Res Opin. 2018 May;34(5):903-910. doi: 10.1080/03007995.2018.1447450. Epub 2018 Mar 27.
5
Metastatic castration-sensitive prostate cancer: Abiraterone, docetaxel, or….转移性去势敏感性前列腺癌：阿比特龙、多西他赛还是……
Cancer. 2019 Jun 1;125(11):1777-1788. doi: 10.1002/cncr.32039. Epub 2019 Apr 1.
6
Abiraterone acetate and prednisolone for metastatic castration-resistant prostate cancer failing androgen deprivation and docetaxel-based chemotherapy: a phase II bridging study in Korean and Taiwanese patients.醋酸阿比特龙和泼尼松龙用于对雄激素剥夺和多西他赛化疗无效的转移性去势抵抗性前列腺癌：一项针对韩国和台湾患者的II期衔接性研究。
Int J Urol. 2014 Dec;21(12):1239-44. doi: 10.1111/iju.12589. Epub 2014 Aug 6.
7
Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer.转移性激素敏感性前列腺癌一线药物治疗的现状及初始治疗的未来展望
Int J Urol. 2016 May;23(5):360-9. doi: 10.1111/iju.13091. Epub 2016 Apr 8.
8
Abiraterone acetate to treat metastatic castration-resistant prostate cancer in combination with prednisone.醋酸阿比特龙联合泼尼松治疗转移性去势抵抗性前列腺癌。
Drugs Today (Barc). 2019 Jan;55(1):5-15. doi: 10.1358/dot.2019.55.1.2914339.
9
[Docetaxel or abiraterone in combination with androgen deprivation therapy for metastatic prostate cancer].多西他赛或阿比特龙联合雄激素剥夺疗法治疗转移性前列腺癌
Urologe A. 2019 Oct;58(10):1185-1197. doi: 10.1007/s00120-019-0953-y.
10
Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis.醋酸阿比特龙与多西他赛联合雄激素剥夺疗法治疗高危和转移性激素初治前列腺癌的比较：系统评价和网络荟萃分析。
Eur Urol. 2018 Jun;73(6):834-844. doi: 10.1016/j.eururo.2017.10.002. Epub 2017 Oct 14.

引用本文的文献

1
Duplicated network meta-analysis in advanced prostate cancer: a case study and recommendations for change.在晚期前列腺癌中重复进行网络荟萃分析：案例研究与变革建议。
Syst Rev. 2022 Dec 16;11(1):274. doi: 10.1186/s13643-022-02137-6.
2
Efficacy and Safety of Androgen-Deprivation Therapy Combined with Docetaxel Plus Prednisone in High-Burden Metastatic Hormone-Sensitive Prostate Cancer.雄激素剥夺疗法联合多西他赛加泼尼松治疗高负荷转移性激素敏感性前列腺癌的疗效与安全性
Cancer Manag Res. 2020 Jun 9;12:4369-4377. doi: 10.2147/CMAR.S243843. eCollection 2020.
3
Expression of FGD4 positively correlates with the aggressive phenotype of prostate cancer.
FGD4 的表达与前列腺癌的侵袭表型呈正相关。
BMC Cancer. 2018 Dec 17;18(1):1257. doi: 10.1186/s12885-018-5096-9.